February 24, 2020

The massive inefficiency of target-based high-throughput screening eventually led to major pivots in the pharmaceutical industry. The biggest was to jump the drug-like small molecule ship altogether and develop biologic drugs (drugs that are proteins/antibodies). This...

January 28, 2020

We’ve been through this before. While it may be convenient to refer to Lipitor as an HMG-CoA reductase inhibitor, or aspirin as a cyclooxegenase inhibitor, or Tom Brady as an “athlete,” they are clearly much more than that.  Hence, being too attached to that conception...

January 25, 2019

Imagine you have discovered a hit compound to treat drug addiction.  Before you drop $1 billion on its development, wouldn’t you want to handicap the odds of its success as best you can?  As we well know we do this poorly, but as the age of machine learning has ta...

December 20, 2018

Pharma small molecule discovery has continued its longtime inexorable decline noted some time ago in this paper.  There is little doubt that the bang for the buck is now a desperate wheeze, as the number of drugs obtained per billion dollars spent on drug development h...

October 18, 2018

The pharmaceutical industry has long stayed humble with their rules for successful drug development: "We’re not bigger than the game!" "We will follow rules even if we don’t understand why they work!" Chris Lipinski’s Rule of 5  is a cornerstone, of course, but only ki...

August 29, 2018

The overlap between seasonal allergies, asthma and eczema has long been recognized. All three are treated by antihistamines, for example, and their histologies match as well, with eosinophils (a type of white blood cell) migrating from the blood into the skin (eczema),...

Please reload



Recent News

Nucleic freeze

April 2, 2020

Surface charm

April 2, 2020

Target practice

April 2, 2020

Please reload